Clinical Research Directory
Browse clinical research sites, groups, and studies.
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Sponsor: Jonsson Comprehensive Cancer Center
Summary
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Official title: Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2015-08-25
Completion Date
2025-01-29
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
Computed Tomography
Undergo FDG PET/CT
Fludeoxyglucose F-18
Undergo FDG PET/CT
Positron Emission Tomography
Undergo FDG PET/CT
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States